Vericiguat and transcatheter edge-to-edge mitral valve repair for combined post- and pre-capillary pulmonary hypertension due to left ventricular low ejection fraction and functional mitral regurgitation.
J Cardiol Cases
; 29(2): 78-81, 2024 Feb.
Article
em En
| MEDLINE
| ID: mdl-38362582
ABSTRACT
A 66-year-old female was diagnosed with combined post- and pre-capillary pulmonary hypertension due to heart failure with reduced ejection fraction (47â¯%) and functional mitral regurgitation [mean pulmonary arterial wedge pressure 27â¯mmHg; pulmonary arterial pressure 91/30 (56) mmHg; pulmonary vascular resistance 12.9 Wood units; and cardiac index 1.77â¯L/min/m2]. Following treatment with vericiguat (a novel oral soluble guanylate cyclase stimulator), hemodynamics improved [mean pulmonary arterial wedge pressure 27â¯mmHg; pulmonary arterial pressure 54/26 (35) mmHg; pulmonary vascular resistance 2.2 Wood units; and cardiac index 2.80â¯L/min/m2]. Therefore, transcatheter edge-to-edge repair for functional mitral regurgitation was performed. One month later, further improvement in hemodynamics was confirmed. Learning objective:
Vericiguat (a novel oral soluble guanylate cyclase stimulator) and transcatheter edge-to-edge mitral valve repair may improve combined post- and pre-capillary pulmonary hypertension due to low ejection fraction of the left ventricle and functional mitral regurgitation.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
J Cardiol Cases
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Japão